Literature DB >> 33942491

Age-related effects on thymic output and homeostatic T cell expansion following depletional induction in renal transplant recipients.

He Xu1, Hui-Jie Lee2, Robin Schmitz1, Brian I Shaw1, Shu Li1, Allan D Kirk1.   

Abstract

Thymic output and homeostatic mature cell proliferation both influence T cell repopulation following depletional induction, though the relative contribution of each and their association with recipient age have not been well studied. We investigated the repopulating T cell kinetics in kidney transplant recipients who underwent alemtuzumab induction followed by belatacept/rapamycin-based immunosuppression over 36-month posttransplantation. We focused specifically on the correlation between repopulating T cell subsets and the age of patients. Substantial homeostatic Ki67-expressing T cell proliferation was seen posttransplantation. A repertoire enriched for naïve T (TNaïve ) cells emerged posttransplantation. Analysis by generalized estimating equation linear models revealed a strong negative linear association between reconstituting TNaïve cells and advancing age. A relationship between age and persistence of effector memory cells was shown. We assessed thymic output and found an increase in the frequency of recent thymic emigrants (RTEs, CD4+ CD31+ ) at 12-month posttransplantation. Patients under 30 years of age showed significantly higher levels of CD4+ CD31+ cells than patients over 55 years of age pre- and posttransplantation. IL-7 and autologous mature dendritic cells (mDCs) induced CD57- cell proliferation. In contrast, mDCs, but not IL-7, induced CD57+ cell proliferation. This study establishes the relationship between age and thymic output during T cell homeostatic repopulation after alemtuzumab induction. Trial Registration: ClinicalTrials.gov - NCT00565773.
© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  basic (laboratory) research/science; clinical research/practice; immunobiology; immunosuppressant - fusion proteins and monoclonal antibodies: alemtuzumab; immunosuppressant - fusion proteins and monoclonal antibodies: belatacept; immunosuppression/immune modulation; immunosuppressive regimens - induction; kidney transplantation/nephrology; lymphocyte biology: differentiation/maturation; lymphocyte biology: proliferation

Mesh:

Substances:

Year:  2021        PMID: 33942491      PMCID: PMC8429231          DOI: 10.1111/ajt.16625

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   9.369


  30 in total

1.  Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance.

Authors:  A D Wells; X C Li; Y Li; M C Walsh; X X Zheng; Z Wu; G Nuñez; A Tang; M Sayegh; W W Hancock; T B Strom; L A Turka
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

2.  Dendritic cell-induced memory T cell activation in nonlymphoid tissues.

Authors:  Linda M Wakim; Jason Waithman; Nico van Rooijen; William R Heath; Francis R Carbone
Journal:  Science       Date:  2008-01-11       Impact factor: 47.728

3.  CD4 T Cell Help via B Cells Is Required for Lymphopenia-Induced CD8 T Cell Proliferation.

Authors:  Katayoun Ayasoufi; Ran Fan; Robert L Fairchild; Anna Valujskikh
Journal:  J Immunol       Date:  2016-02-24       Impact factor: 5.422

4.  Designing and maintaining the mature TCR repertoire: the continuum of self-peptide:self-MHC complex recognition.

Authors:  C Viret; F S Wong; C A Janeway
Journal:  Immunity       Date:  1999-05       Impact factor: 31.745

5.  Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.

Authors:  R Ferguson; J Grinyó; F Vincenti; D B Kaufman; E S Woodle; B A Marder; F Citterio; W H Marks; M Agarwal; D Wu; Y Dong; P Garg
Journal:  Am J Transplant       Date:  2010-11-29       Impact factor: 8.086

6.  Survival and homeostatic proliferation of naive peripheral CD4+ T cells in the absence of self peptide:MHC complexes.

Authors:  S R Clarke; A Y Rudensky
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

7.  Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

Authors:  Allan D Kirk; Douglas A Hale; Roslyn B Mannon; David E Kleiner; Steven C Hoffmann; Robert L Kampen; Linda K Cendales; Douglas K Tadaki; David M Harlan; S John Swanson
Journal:  Transplantation       Date:  2003-07-15       Impact factor: 4.939

Review 8.  The biology of recent thymic emigrants.

Authors:  Pamela J Fink
Journal:  Annu Rev Immunol       Date:  2012-11-01       Impact factor: 28.527

9.  An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation.

Authors:  A Cherukuri; A D Salama; C Carter; N Smalle; R McCurtin; E W Hewitt; M Hernandez-Fuentes; B Clark; R J Baker
Journal:  Am J Transplant       Date:  2012-03-05       Impact factor: 8.086

10.  B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells.

Authors:  S Heidt; J Hester; S Shankar; P J Friend; K J Wood
Journal:  Am J Transplant       Date:  2012-03-15       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.